Betapace AF Education Will Emphasize Use Only For Severe Symptoms
Executive Summary
Berlex' Betapace AF educational program should emphasize use only in highly symptomatic patients, FDA said in its Feb. 22 approval letter for sotalol for atrial fibrillation and atrial flutter.